Enhertu, Senescence, and the Senolytic Second Strike

How trastuzumab deruxtecan interacts with cellular senescence and dormancy — and why a timed senolytic strategy may matter after each cycle.

Enhertu is one of the most important recent advances in HER2-targeted treatment.

It can produce deep responses.

It still does not kill every cancer cell it reaches.

Some surviving cells may enter therapy-induced senescence.

Others may shift into autophagy-dependent dormancy.

That is why a second-strike strategy gets discussed after each cycle.

Why this matters

The main question is not whether Enhertu works.

It clearly does.

The harder question is what damaged surviving cells do next.

If a cell does not die, it may:

stop dividing but stay metabolically active
release inflammatory SASP signals
remain quiet in a dormant state
later re-enter growth

How Enhertu works — and what makes it different from standard chemotherapy

T-DXd is an antibody-drug conjugate, also known as an ADC for short.

It works like a guided missile.

It has three parts:

an antibody that seeks out cancer cells
a potent chemotherapy payload
a linker that joins them

The antibody portion locks onto HER2 on the cancer-cell surface.

It delivers the drug inside the cell.

The payload is then released to kill it.

This targeted delivery means chemotherapy reaches cancer cells at much higher concentrations.

Healthy cells see far less exposure than they would with standard chemotherapy.

Specifically, T-DXd joins Trastuzumab to a potent topoisomerase I inhibitor payload, Deruxtecan, through a tumour-selective cleavable linker.

The linker is mainly cleaved by enzymes that are up-regulated inside tumour cells.

That means the payload is released predominantly inside cancer cells that express HER2.

That can include low (1+), moderate (2+), or high (3+) expression.

This is fundamentally different from conventional chemotherapy.

Standard chemotherapy distributes systemically.

It damages healthy dividing cells throughout the body.

That difference matters for senescence risk in healthy tissue.

Classic chemotherapies such as doxorubicin and cisplatin are well documented to drive therapy-induced senescence in healthy stromal cells.

That includes fibroblasts, endothelial cells, and immune cells.

Those senescent healthy cells can then develop a SASP.

That inflammatory program can remodel the tumour microenvironment in ways that support survival, awaken dormant cells, and facilitate metastasis.

With T-DXd, the payload reaches normal tissue at much lower concentrations.

That should reduce — but not eliminate — the risk of widespread healthy-cell senescence.

There is still an important nuance.

T-DXd also carries a bystander effect.

The cleaved payload can diffuse from HER2-expressing targeted cells into adjacent HER2-negative cells.

That is a deliberate and useful feature.

It helps T-DXd kill heterogeneous tumour populations.

It also means not every cell under cytotoxic pressure was directly targeted by the antibody.

That matters when thinking about why some cells die, while others enter senescence or dormancy.

How Enhertu can create therapy-induced senescence in cancer cells

The topoisomerase I inhibitor payload in T-DXd causes DNA double-strand breaks inside cancer cells.

Not all cancer cells respond by dying immediately.

Some instead enter therapy-induced senescence.

That may be more likely in cells with lower HER2 surface expression, partial payload exposure, or pre-existing DNA-damage-response adaptations.

The DNA damage is still real.

The difference is that the cell activates p21- or p16-mediated cell-cycle arrest instead of apoptosis.

This is not only theoretical.

Research published in Cancer Research in 2022 directly linked therapy-induced senescence to HER2-targeted ADCs.

That work showed senescence can enhance the bystander effect by creating a pro-inflammatory microenvironment that increases payload diffusion into neighbouring HER2-negative cells.

That creates a double edge.

In the short term, senescence may amplify T-DXd's reach.

Over later cycles, surviving senescent cancer cells can develop a SASP that supports the surrounding tumour tissue.

That SASP can include:

pro-inflammatory interleukins such as IL-6 and IL-8
growth factors such as HGF and VEGF
matrix metalloproteinases

Together, those signals can support persistence, immune evasion, and recurrence.

Unlike some conventional chemotherapies, where the SASP also comes from stressed healthy stromal cells, Enhertu concentrates the main senescence risk inside the tumour-cell population itself.

That is still a problem.

It is just a more localised one.

The senolytic strategy after Enhertu: why, what, and when

Senolytics are compounds that selectively eliminate senescent cells.

That selectivity has a mechanistic basis.

Senescent cells, including therapy-induced senescent cancer cells, often upregulate anti-apoptotic survival proteins.

These commonly include BCL-2, BCL-xL, and BCL-W.

They do this to resist the cell death that their DNA damage should otherwise trigger.

Senolytics exploit that dependency.

Some target those anti-apoptotic proteins directly.

Others generate ROS at levels that overwhelm the oxidative stress senescent cells already carry.

In both cases, senescent cells are hit more selectively than cells with normal apoptotic thresholds.

Drug-Supplement Interaction Context

Enhertu is NOT metabolized by the CYP3A4 enzyme pathway.

This is important because many natural compounds and supplements do interact with CYP3A4. Some of the compounds in this senolytic stack below— particularly quercetin and piperlongumine — can affect CYP3A4 enzyme activity.

Enhertu itself does not rely on this pathway for clearance, the direct interaction risk with Enhertu is lower than it would be with CYP3A4-dependent chemotherapies.

Enhertu has fewer potential conflicts with senolytic or autophagy-targeting compounds than chemotherapies that rely heavily on CYP3A4 for clearance.

However, this does not mean all interactions are safe.

Always discuss supplement use with your oncology team before combining with any cancer treatment.

Why stack multiple senolytics rather than use one alone

Not all therapy-induced senescent cells are the same.

Different cells enter senescence through different molecular routes.

Some depend more on BCL-xL.

Others lean on BCL-2 or BCL-W.

Some are more vulnerable to ROS-driven killing.

Others respond better to direct BH3-mimetic pressure.

A single senolytic only covers the subset that matches its mechanism.

A stacked combination broadens coverage.

That is why combination logic keeps coming up after T-DXd.

The natural senolytic stack: what each compound does

Fisetin — liposomal forms are often preferred. It is the most extensively studied natural senolytic. It inhibits BCL-2 and BCL-xL, suppresses NF-κB, reduces SASP output, activates pro-apoptotic proteins such as Bax, Bak, and Bad, and can trigger caspase-mediated apoptosis in senescent cells. At lower concentrations, it can also act as a senomorphic.
Quercetin — liposomal forms are often preferred. It is the most studied senolytic flavonoid in human clinical research. The dasatinib + quercetin pairing is the leading pharmaceutical senolytic combination in trials. Quercetin targets the PI3K/Akt survival pathway and suppresses transcriptional machinery that drives SASP production.
Luteolin — this flavone inhibits STAT3 and NF-κB, two transcription factors central to SASP maintenance and senescent-cell survival. It can reduce IL-6 and IL-8 output, suppress JAK-STAT signalling, and add anti-proliferative pressure against cells that escape senescence.
Apigenin — this flavone can promote apoptosis in senescent cells through p53 activation and CDK inhibition. It also suppresses mTOR, which may matter for dormancy-adjacent cells that coexist with senescent survivors after T-DXd.
Piperlongumine — It is one of the most selectively cytotoxic natural senolytic compounds identified so far. It inhibits Thioredoxin Reductase 1 (TrxR1), which is overexpressed in senescent and cancer cells, and drives lethal ROS accumulation in cells already under oxidative stress.
For all, expcept quercetin, liposomal forms are required.

This remains an emerging strategy.

It is not standard oncology care.

The strongest support is still mechanistic and preclinical.

Direct Enhertu-specific senolytic trial data remains limited.

Related: Senolytic Pulse Protocol

Timing the senolytic stack around Enhertu cycles

Timing is not a scheduling preference.

It is a mechanistic necessity.

Senolytics should not be used during active Enhertu treatment.

During the infusion window, the goal is to let T-DXd do its primary work.

That includes payload delivery, DNA damage, and bystander killing.

Introducing senolytics at that point could interfere with the therapy-induced senescence that may temporarily amplify bystander reach.

The more rational approach is an intermittent pulsed protocol.

It is sometimes described as a hit-and-run strategy.

Enhertu is typically given every three weeks.

Its half-life is about 6 days.

That supports waiting until the main cytotoxic phase has largely completed.

It also gives senescent cancer survivors time to accumulate into a clearer target population.

The senolytic pulse can then begin around days 10 to 11 after infusion.

It can run for 5 to 7 consecutive days.

It should end well before the next cycle.

Illustrative three-week Enhertu cycle with senolytic pulse

Days post-infusion	Phase	Senolytic stack
Day 0	Enhertu infusion	Do not use
Days 1–9	Primary cytotoxic phase — payload active	Do not use
Days 10–16	Recovery phase — senescent cells accumulating	Begin senolytic pulse
Days 17–20	Pre-next-cycle clearance window	End pulse and allow washout
Day 21	Next Enhertu infusion	Do not use — the cycle repeats

This timing is not a rigid prescription.

Individual cycles, response, and tolerability still matter.

The core principle is simple.

Let the first strike act first.

Then clear what it leaves behind before the next cycle.

Continuous daily senolytic use is not the goal.

That approach is not supported by the evidence.

Senescent cells need time to re-accumulate.

Continuous exposure may increase tissue burden without improving clearance.

What this strategy is not

It helps to keep the boundaries clear.

It is not a replacement for Enhertu.
It is not a claim that all surviving cells are senescent.
It is not a reason to use continuous daily senolytics.
It is not proof of clinical benefit yet.

It is a way to think more clearly about the cells that survive the cycle.

Practical takeaway

Enhertu changes the senescence question.

The main issue is less about widespread healthy-tissue senescence.

It is more about local tumour-cell survivors.

Those survivors may be senescent.

They may contribute to later persistence if they are left alone.

That makes a timed post-cycle follow-up strategy biologically reasonable.

The current evidence best supports this framing:

Enhertu can leave behind senescent tumour cells
a timed senolytic pulse after each (or every second) cycle makes more sense than overlap or daily use
the whole idea remains investigational and ideally should be clinician-supervised

Would you like to ask Abbey and or Maria a question about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

Part Two:

Can Enhertu also create dormant cancer cells?

This is the harder question.

The most honest answer is probably yes, in a subset of cells.

Dormancy and senescence overlap.

They are not the same state.

A dormant cancer cell is deeply quiescent.

It is not necessarily defined by a heavy SASP or by permanent cell-cycle arrest.

It is more like a cell that has pressed pause.

A senescent cell has a more permanent-seeming arrest and active secretory behaviour.

The key link between T-DXd treatment and dormancy is autophagy.

Dormant cancer cells, including disseminated breast-cancer cells at distant sites, are strongly autophagy-dependent for long-term survival.

Preclinical studies show that genetic or pharmacological autophagy inhibition using hydroxychloroquine can markedly reduce dormant-cell survival and metastatic burden.

Any cancer cell that survives Enhertu by entering a quiescent or sub-lethally damaged state is likely to become more autophagy-dependent than it was before treatment.

Autophagy is the machinery that keeps stressed, resource-limited cells alive when they cannot proliferate.

There is also evidence from the broader ADC and breast-cancer literature that autophagy inhibition can prevent escape from chemotherapy-induced dormancy.

At the same time, autophagy-deficient breast-cancer cells can show early escape from dormancy and recurrence because they cannot maintain a stable arrested state.

So the relationship is not as simple as "block autophagy and kill dormant cells."

It is more timing-dependent than that.

Sustained autophagy blockade during the dormant window may prevent the cell from maintaining quiescence and force it into a crisis it cannot survive.

The timing and consistency of that pressure matter.

We are continuing with the HER2+ Specific Dormancy and Autophagy integrative treatment research but in the meantime please read these pages and reach out via the feedback form.

Key references

Deruxtecan-based antibody–drug conjugates induce senescence in HER2-positive breast cancer — Vezzoli E, Pinos R et al., Scientific Reports, 2026\ Read the paper
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer\ Read the paper
Open-access version of the same 2022 study\ Read the paper
Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence\ Read the paper
Autophagy and Cancer Dormancy\ Read the review
Autophagy-deficient breast cancer shows early tumour recurrence and escape from dormancy\ Read the paper
Therapy-induced senescence is finally escapable, what is next?\ Read the PubMed record
Cellular senescence and SASP in tumour progression and therapeutic resistance\ Read the review
The Roles of Autophagy and Senescence in the Tumor Cell Response to Treatment\ Read the review
Targeting Cellular Senescence with Liposome-Encapsulated Fisetin\ Read the paper
Biological effects and mechanisms of fisetin in cancer\ Read the review
Piperlongumine, a novel TrxR1 inhibitor, induces apoptosis via ROS-dependent ER stress\ Read the paper
Senolytic activity of piperlongumine analogues\ Read the paper
Enhertu improves survival in metastatic HER2-low breast cancer\ Read the NCI summary
Pharmacokinetics and mechanism summary for trastuzumab deruxtecan\ Read the eviQ summary